Drug Discovery Opinion

A new study describes a high affinity interaction between siramesine and phosphatidic acid, a component of cell membranes that also acts as a signalling molecule. Siramesine is a sigma receptor agonist, selective for the σ2 subtype, which was originally under development for the treatment of anxiety but failed to show efficacy in clinical trials.

Siramesine was subsequently shown to kill cancer cells by destabilising their lysosomes. Vincristine, a microtubule destabilising antimitotic drug, which is used in various chemotherapy regimens, greatly sensitised cancer cells to the cytotoxic effects of siramesine.

The new study suggests that it may be possible to design small molecules to specifically scavenge phospholipids involved in the signalling cascades controlling cell survival.

Bookmark It

Hide Sites

Related posts:

1. Study Casts New Light on Prozac Mechanism Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac®) have been used to treat depression for more than three decades...
2. New Anti-Cancer Bisphosphonates Bisphosphonates prevent loss of bone mass and are used to treat postmenopausal osteoporosis and also to reduce bone loss in...
3. Phase III Study for Oxidative Stress Inducer, Elesclomol Synta Pharmaceuticals has recently announced enrolment of 630 patients for a pivotal Phase III trial of elesclomol (STA-4783) in patients...
4. New Insights into DJ-1/PARK7 Oncogenic Mechanism Loss-of-function mutations of human DJ-1/PARK7 are associated with autosomal recessive, early onset Parkinson’s disease. In contrast, amplification of DJ-1 has...
5. Mechanism of PPAR-γ Activators in Tumour Suppression Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that play essential roles in the regulation of cellular differentiation, development and metabolism....

Related posts brought to you by Yet Another Related Posts Plugin.

 Email This Post

This entry was posted on Thursday, September 18th, 2008 at 8:50 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.